Medtronic began fiscal year 2027 with strong first-quarter results, exceeding expectations with 7% normalized revenue growth driven by its Cardiovascular and Neuroscience segments. The company raised its revenue and earnings per share guidance, although margin expansion is expected to be gradual as the product mix shifts toward higher-margin recurring revenues. The recent MiniMed separation is expected to improve Medtronic's margin profile. Additionally, strong free cash flow and a flexible balance sheet support potential share repurchases and acquisitions. Analysts have initiated coverage on Medtronic with a buy rating and a price target of $106.33, implying a 17% upside and a 3% dividend yield.
Medtronic offers a 3.14% dividend yield on Pluang, slightly above the 3% yield mentioned in the article, highlighting its appeal for income-focused investors. Despite the upbeat fiscal year start and raised guidance, MDT shares are trading at USD 90.90, down 0.93% as of Sep 24, 2026 03:02 WIB, below its 52-week high of USD 105.35. The stock sees a high sell activity of 83% on Pluang, reflecting cautious sentiment among platform users amid the company’s gradual margin expansion and strategic shifts.
